Compare CLIR & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLIR | BOLD |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 36.5M |
| IPO Year | 2011 | 2024 |
| Metric | CLIR | BOLD |
|---|---|---|
| Price | $4.81 | $1.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $4.00 |
| AVG Volume (30 Days) | 12.7K | ★ 130.8K |
| Earning Date | 04-09-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $530,000.00 | N/A |
| Revenue This Year | $34.29 | N/A |
| Revenue Next Year | $67.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $0.96 |
| 52 Week High | $7.56 | $1.68 |
| Indicator | CLIR | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 50.61 | 48.89 |
| Support Level | $4.18 | $1.42 |
| Resistance Level | $5.56 | $1.55 |
| Average True Range (ATR) | 0.41 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 46.01 | 20.75 |
ClearSign Technologies Corp is engaged in designing and develop technologies for the purpose of decarbonization and improving key performance characteristics of industrial and commercial combustion systems, including emission and operational performance, energy efficiency and overall cost-effectiveness. Its ClearSign Core technology has been proved to be in full scale industrial test furnaces and boilers and first customer installations are currently operating in normal commercial applications The company offers products that include process burners, boiler burners, flares, and ClearSign Eye. The company operates in one segment: Combustion segment. The products of the company include: Process Burners, Midstream and Power, Flares, Boiler Burners, and Sensing Technology.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.